{"organizations": [], "uuid": "000b45429d9414a3aa1cfb954418bd8f65ed5b97", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-emergent-biosolutions-and-valneva/brief-emergent-biosolutions-and-valneva-initiate-clinical-study-to-evaluate-vaccine-against-zika-virus-idUSFWN1QG19V", "country": "US", "domain_rank": 408, "title": "BRIEF-Emergent Biosolutions And Valneva Initiate Clinical Study To Evaluate Vaccine Against Zika Virus", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T00:23:00.000+02:00", "replies_count": 0, "uuid": "000b45429d9414a3aa1cfb954418bd8f65ed5b97"}, "author": "", "url": "https://www.reuters.com/article/brief-emergent-biosolutions-and-valneva/brief-emergent-biosolutions-and-valneva-initiate-clinical-study-to-evaluate-vaccine-against-zika-virus-idUSFWN1QG19V", "ord_in_thread": 0, "title": "BRIEF-Emergent Biosolutions And Valneva Initiate Clinical Study To Evaluate Vaccine Against Zika Virus", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "evaluate vaccine against zika virus", "sentiment": "negative"}, {"name": "vaccine against zika virus reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "emergent biosolutions inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Emergent Biosolutions Inc:\n* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS\n* EMERGENT BIOSOLUTIONS INC - INITIAL DATA FROM PHASE 1 CLINICAL TRIAL OF VLA1601 ARE EXPECTED TO BE AVAILABLE IN LATE 2018 OR EARLY 2019 Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-27T00:23:00.000+02:00", "crawled": "2018-02-27T00:43:22.026+02:00", "highlightTitle": ""}